Growth Hormone AxisIn StockGrowth Hormone Axis
Hexarelin
Also known as: Examorelin
Synthetic hexapeptide GHS-R1a agonist with a D-MethylTrp modification; notable cardiac-research profile.
Hexarelin (examorelin) is a synthetic hexapeptide growth-hormone-releasing peptide with a characteristic 2-methyl-D-tryptophan modification at position 2.
It was developed in the 1990s and is recognized in the research literature for both its GH-releasing activity and its interactions with CD36 — a scavenger receptor expressed in cardiac and immune tissues.Research applications for Hexarelin extend beyond the GH/IGF-1 axis into cardiac-tissue protection, CD36 ligand pharmacology, and ischemia-reperfusion models.
Published investigations have explored its potential roles in both the pituitary and non-pituitary tissues in which GHS-R1a or CD36 are expressed.Hexarelin occupies a more specialized niche than GHRP-2 or GHRP-6, with particular interest in cardiovascular-research contexts.
Research applications
- GHS-R1a and CD36 dual-receptor pharmacology
- Cardiac tissue protection and ischemia models
- Comparative GHRP-family research
- Scavenger receptor biology
- Peripheral (non-pituitary) growth-hormone-secretagogue signaling
Technical profile
- Net content
- 5 mg
- Molecular formula
- C47H58N12O6
- Molecular weight
- 887.03 g/mol
- CAS
- 140703-51-1
- Sequence
- His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2
For research use only. Not for human or veterinary consumption. Not intended to diagnose, treat, cure, or prevent any disease. Catalog availability restricted to verified licensed practitioners.
Hexarelin is a synthetic hexapeptide growth hormone secretagogue that activates the ghrelin receptor (GHS-R1a). It produces robust GH release and is also studied for its cardioprotective properties and effects on cardiac remodeling.
